All filters
Slidesets
Clinical Pharmacology related considerations- David Back, PhD
Presented at:
Global HIV Clinical Forum 2017
Slidesets
Pediatric use of Integrase Inhibitors- Mark Cotton, MD, PhD
Presented at:
Global HIV Clinical Forum 2017
Slidesets
Optimal Use of Integrase Inhibitors in Women- Sharon Walmsley, FRCPC, MD, MSC
Presented at:
Global HIV Clinical Forum 2017
Slidesets
Mutations to Integrase inhibitors in real life- Dr. Isabel Viciana Ramos
Presented at:
Global HIV Clinical Forum 2017
Slidesets
The Role of Integrase Inhibitors during HIV prevention- Pep Coll, MD
Presented at:
Global HIV Clinical Forum 2017
Slidesets
Clinical Case -Reduced Drug Regimen- Pedro Cahn, MD, PhD
Presented at:
Global HIV Clinical Forum 2017
Slidesets
Optimizing Clinical Utility of Integrase Inhibitors- Anton Pozniak, MD, FRCP
Presented at:
Global HIV Clinical Forum 2017
Slidesets
Current and Future Treatment of CMV- Robin Avery, MD
Presented at:
International Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2017
Slidesets
O_1: Single- and multiple-ascending doses (SAD/MAD) and food effect of orally administered JNJ-64155806 in healthy volunteers- Thomas Kakuda, PharmD
Presented at:
International Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2017
Slidesets
O_2: Effects of cobicistat on tenofovir durability: is it time to rethink at TAF trials?- Dario Cattaneo, PharmD, PhD
Presented at:
International Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2017
Slidesets
O_4: Evaluation of the Drug-Drug Interaction Potential between Cobicistat-Boosted Protease Inhibitors and Statins - Dr Joseph Custodio
Presented at:
International Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2017
Slidesets
O_5: Confirmation of the drug-drug interaction (DDI) potential between cobicistat-boosted antiretroviral regimens and hormonal contraceptives- Dr Sophia Majeed
Presented at:
International Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2017
Slidesets
O_3: Pharmacokinetics of darunavir/cobicistat and etravirine alone and coadministered in HIV-infected patients- José Moltó, MD, PhD
Presented at:
International Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2017
Slidesets
O_6: Darunavir concentrations in CSF of HIV-infected individuals when boosted with cobicistat versus ritonavir- Catia Marzolini, PharmD, PhD
Presented at:
International Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2017
Slidesets
Current Challenges in Pediatric Drug Development- Robert Ward, MD, FAAP, FCP
Presented at:
International Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2017
Slidesets
Clinical Aspects of Pediatric Treatment- Tim Cressey, PhD
Presented at:
International Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2017
Slidesets
O_8: Relationship between dolutegravir plasma exposure, quality of sleep and its functional outcome in patients living with HIV over the age of 60 years.- Marta Boffito, MD, PhD, FRCP
Presented at:
International Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2017
Slidesets
O_7: A Comparison of the Pharmacokinetics of Dolutegravir during Pregnancy and Postpartum- Dr Pauline Bollen
Presented at:
International Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2017
Slidesets
O_11: HIV-1-infected Males and Females under Less-Drug Regimens Achieve Antiretroviral Levels above the Inhibitory Concentration in the Genital Tract.- Sandrine Lefeuvre
Presented at:
International Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2017